Novartis secures rights to Mesoblast’s remestemcel-L for ARDS by Lucy Parsons | Nov 20, 2020 | News | 0 Drug is currently being evaluated in a phase III COVID-19-related ARDS study Read More
Faron stock falls on traumakine failure by Selina McKee | May 9, 2018 | News | 0 Shares Finnish group Faron Pharmaceuticals were trading down more than 80 percent on the London Stock Exchange after its key drug traumakine failed in acute respiratory distress syndrome (ARDS). Read More